Responses
Regular and Young Investigator Award Abstracts
Clinical Trial Completed
599 Single-agent safety and activities of target-preserving anti-CTLA-4 antibody gotistobart (ONC-392/BNT316) in PD-(L)1 resistant metastatic NSCLC and population PK analysis in patients with solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.